GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » Debt-to-Revenue

PuraPharm (HKSE:01498) Debt-to-Revenue : 1.04 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is PuraPharm Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

PuraPharm's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$264.2 Mil. PuraPharm's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$99.6 Mil. PuraPharm's annualized Revenue for the quarter that ended in Dec. 2024 was HK$348.9 Mil. PuraPharm's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 1.04.


PuraPharm Debt-to-Revenue Historical Data

The historical data trend for PuraPharm's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm Debt-to-Revenue Chart

PuraPharm Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 0.81 1.12 1.04 0.95

PuraPharm Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 1.17 1.00 0.99 1.04

Competitive Comparison of PuraPharm's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PuraPharm's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where PuraPharm's Debt-to-Revenue falls into.


;
;

PuraPharm Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

PuraPharm's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(264.181 + 99.578) / 382.09
=0.95

PuraPharm's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(264.181 + 99.578) / 348.926
=1.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.


PuraPharm Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of PuraPharm's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PuraPharm Business Description

Traded in Other Exchanges
N/A
Address
Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. The organization provides Chinese medical diagnostic services and operates through several segments: China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation, and Clinics. The majority of its revenue comes from the Hong Kong CCMG segment, which mainly involves the sale of CCMG products, excluding sales through self-operated clinics in Hong Kong. The group derives revenue from customers located in Hong Kong, Mainland China, and Other countries.
Executives
Chan Yu Ling, Abraham 2101 Beneficial owner
Man Yee Wai, Viola 2202 Interest of your spouse
Fullgold Development Limited 2101 Beneficial owner

PuraPharm Headlines

No Headlines